Synairgen (SNG)

 

SNG Share PerformanceMore

52 week high38.00 25/04/16
52 week low12.10 04/01/17
52 week change 7.75 (33.70%)
4 week volume3,569,174 27/02/17

Media for (SNG)

Presenter: Richard Marsden, CEO
11/11/2014
Presenter: Richard Marsden
08/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 3085Z Synairgen plc 13 March 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Synairgen Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acquisition or disp...

Additional Positive Data in Lung Fibrosis

RNS Number: 1286Z Synairgen plc 10 March 2017 Press release Synairgen plc ('Synairgen' or the 'Company') Additional Positive Data in Lung Fibrosis - Phase I clinical trial scheduled to start in H2 2017 Southampton, UK - 10 March 2017: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces further positive data from it...

Holding(s) in Company

RNS Number: 3878U Synairgen plc 17 January 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Synairgen plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or dis...

Holding(s) in Company

RNS Number: 4682M Synairgen plc 13 October 2016 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Synairgen plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights x An acquisition or dis...

Synairgen updates on AZD9412

Synairgen (SNG) has confirmed that AstraZeneca has decided to stop the Phase IIa trial for AZD9412 based on an interim ...

FTSE up on airlines, house builders after sluggish start

London stocks shrugged offer an early sour start to be cautiously ahead, with both the blue-chip and mid-cap indices risin...

AZD9412 Clinical Trial Update

RNS Number: 2831M Synairgen plc 12 October 2016 Press release Synairgen plc ('Synairgen' or the 'Company') AZD9412 Clinical Trial Update ~ AstraZeneca to focus on key secondary endpoints with results expected in Q1 2017 ~ Southampton, UK - 12 October 2016: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announced today t...

Broker Forecast - N+1 Singer issues a broker note on Synairgen PLC

N+1 Singer today reaffirms its buy investment rating on Synairgen PLC (LON:SNG) and cut its price target to 46p (from 4...

Fundamental DataMore

EPS-2.47
Dividend yield0 %

Equity Research (SNG)

edison investment research
Synairgen
14/07/2014
The recent exclusive global deal with AstraZeneca, potentially worth $230m, to in-license SNG001 for the treatment of asthma is a strong validation of Synairgen’s in-vitro cell-based approach using...

Latest discussion posts More

  • Re: :-)

    Yes very encouraging. Also waiting for the akzo decision or not? Thanks for the tippage. Up a great deal again!
    10-Mar-2017
    high blood pressure1
  • Re: :-)

    Yes very encouraging. Also waiting for the akzo decision or not? 5th and for the tippage. Up a great deal again!
    10-Mar-2017
    high blood pressure1
  • :-)

    Well, thats good news isnt it.? :-)
    10-Mar-2017
    Disorder

Users' HoldingsMore

Users who hold Synairgen also hold..
PREMIER OIL20%
SIRIUS MINERALS17%
VECTURA14%
ID:ISIN:VGG9828A119414%
ADVANCED ONCO14%

Codes & Symbols

ISINGB00B0381Z20
SymbolsSNG, LSE:SNG, SNG.L, SNG:LN, LON:SNG, XLON:SNG